医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Yong Chul Shin, Ph.D., is Chief Scientific Officer of Lysando AG

2023年04月13日 PM04:01
このエントリーをはてなブックマークに追加


 

TRIESENBERG, Liechtenstein

Lysando AG – market leader in the field of antimicrobial proteins – is pleased to announce that Dr. Yong Chul Shin has joined the team as CSO in April. Dr. Shin will be responsible for leading the company’s scientific strategy and represents Lysando in science-related communication – particularly to the Korean market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230413005080/en/

Dr. Yong Chul Shin - CSO Lysando AG

Dr. Yong Chul Shin – CSO Lysando AG

Dr. Shin is a prominent researcher and biotech entrepreneur, holding a Ph.D. in Molecular Biology. He has over 30 years of experience in the biotechnology industry.

“With their first product in the market and a promising pipeline I see a bright future for Lysando, and I am excited to be part of this journey as we continue to push the boundaries of what is possible through science and innovation”, says newly appointed CSO, Dr. Yong Chul Shin.

Dr. Shin has a strong track record of successful product development and commercialization in the areas of biopharmaceuticals, industrial enzymes, and microbial strains. He served in various senior roles in several biotechnology companies, including as founder and Chief Executive Officer at Korean biotech Amicogen Inc. (KOSDAQ: A092040). Amicogen is a leader in the development and production of specialty enzymes and proteins for the biopharmaceutical, food, cosmetics, and other industries. To Lysando, Dr. Shin’s expertise is an important asset to accelerate the time to market for innovative products to combat antibiotic-resistant bacteria.

“We conducted extensive research to find the best candidate for this position, and it was clear from the start that Dr. Shin was the perfect fit for our organization”, says Count Markus Matuschka de Greiffenclau, Chairman of the Board of Directors of Lysando AG. “His leadership qualities and track record of success speak for themselves, and we are confident that with Dr. Shin joining, our team has been further strengthened and our ties with Korea – a world-leading hub for biotechnology – have become much closer.”

The appointment of Dr. Shin as Chief Scientific Officer is a significant development for Lysando AG, proving the company’s commitment to invest in top talent and expand its capabilities.

About Lysando AG

Lysando AG is market leader for antimicrobial proteins, so-called Artilysin® molecules. They can effectively eliminate problem-causing bacteria without associated high risk of resistance formation and microbial disbalances. Artilysin® constitutes an innovative, proprietary and environmentally friendly technology with a wide range of applications: in human and veterinary medicine, but for example also in cosmetics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005080/en/

CONTACT

Verena Schossmann

Tel.: +41(0)79 211 83 42

E-Mail: Verena.Schossmann@lysando.com

TimeLine: ,

同じカテゴリーの記事 

  • Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan
  • Imricor’s VISABL-AFL Trial for US FDA Approval Commences at Cardiovascular Institute of South Paris
  • Southeast Asian Countries Lead in Positive Experiences
  • Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
  • Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver